The  ||| S:0 E:4 ||| DT
suppression  ||| S:4 E:16 ||| NN
of  ||| S:16 E:19 ||| IN
a  ||| S:19 E:21 ||| DT
herpes  ||| S:21 E:28 ||| JJ
simplex  ||| S:28 E:36 ||| JJ
virus  ||| S:36 E:42 ||| NN
reproduction  ||| S:42 E:55 ||| NN
with  ||| S:55 E:60 ||| IN
drug  ||| S:60 E:65 ||| NN
resistance  ||| S:65 E:76 ||| NN
by  ||| S:76 E:79 ||| IN
combination  ||| S:79 E:91 ||| NN
15lys-bis-nt  ||| S:91 E:104 ||| NN
and  ||| S:104 E:108 ||| CC
phosphate  ||| S:108 E:118 ||| NN
of  ||| S:118 E:121 ||| IN
acycloguanosine  ||| S:121 E:137 ||| NN
with  ||| S:137 E:142 ||| IN
some  ||| S:142 E:147 ||| DT
antiherpetic  ||| S:147 E:160 ||| JJ
drugs  ||| S:160 E:166 ||| NNS
Antiherpetic  ||| S:166 E:179 ||| JJ
activity  ||| S:179 E:188 ||| NN
of  ||| S:188 E:191 ||| IN
the  ||| S:191 E:195 ||| DT
double  ||| S:195 E:202 ||| JJ
and  ||| S:202 E:206 ||| CC
triple  ||| S:206 E:213 ||| JJ
combinations ||| S:213 E:225 ||| NNS
,  ||| S:225 E:227 ||| ,
including  ||| S:227 E:237 ||| VBG
original  ||| S:237 E:246 ||| JJ
connections  ||| S:246 E:258 ||| NNS
15Lys-bis-Nt  ||| S:258 E:271 ||| NNP
and  ||| S:271 E:275 ||| CC
phosphate  ||| S:275 E:285 ||| NN
of  ||| S:285 E:288 ||| IN
acycloguanosine  ||| S:288 E:304 ||| NNS
( ||| S:304 E:305 ||| -LRB-
P-ACG ||| S:305 E:310 ||| NNP
) ||| S:310 E:311 ||| -RRB-
,  ||| S:311 E:313 ||| ,
was  ||| S:313 E:317 ||| VBD
studied  ||| S:317 E:325 ||| VBN
in  ||| S:325 E:328 ||| IN
vitro ||| S:328 E:333 ||| NN
.  ||| S:333 E:335 ||| .
For  ||| S:335 E:339 ||| IN
the  ||| S:339 E:343 ||| DT
first  ||| S:343 E:349 ||| JJ
time ||| S:349 E:353 ||| NN
,  ||| S:353 E:355 ||| ,
it  ||| S:355 E:358 ||| PRP
was  ||| S:358 E:362 ||| VBD
demonstrated  ||| S:362 E:375 ||| VBN
that  ||| S:375 E:380 ||| IN
in  ||| S:380 E:383 ||| IN
case  ||| S:383 E:388 ||| NN
of  ||| S:388 E:391 ||| IN
their  ||| S:391 E:397 ||| PRP$
combined  ||| S:397 E:406 ||| JJ
use  ||| S:406 E:410 ||| NN
with  ||| S:410 E:415 ||| IN
known  ||| S:415 E:421 ||| VBN
antiherpetic  ||| S:421 E:434 ||| JJ
agents ||| S:434 E:440 ||| NNS
,  ||| S:440 E:442 ||| ,
whose  ||| S:442 E:448 ||| WP$
activity  ||| S:448 E:457 ||| NN
does  ||| S:457 E:462 ||| VBZ
not  ||| S:462 E:466 ||| RB
depend  ||| S:466 E:473 ||| VB
on  ||| S:473 E:476 ||| IN
TK  ||| S:476 E:479 ||| NNP
of  ||| S:479 E:482 ||| IN
HSV  ||| S:482 E:486 ||| NNP
( ||| S:486 E:487 ||| -LRB-
PFA ||| S:487 E:490 ||| NNP
,  ||| S:490 E:492 ||| ,
AraA ||| S:492 E:496 ||| NNP
,  ||| S:496 E:498 ||| ,
CDV ||| S:498 E:501 ||| NNP
,  ||| S:501 E:503 ||| ,
Rib ||| S:503 E:506 ||| NNP
,  ||| S:506 E:508 ||| ,
GLN ||| S:508 E:511 ||| NNP
,  ||| S:511 E:513 ||| ,
Î±a-IFN ||| S:513 E:519 ||| NNP
) ||| S:519 E:520 ||| -RRB-
,  ||| S:520 E:522 ||| ,
synergistic  ||| S:522 E:534 ||| NN
or  ||| S:534 E:537 ||| CC
additive  ||| S:537 E:546 ||| JJ
effects  ||| S:546 E:554 ||| NNS
of  ||| S:554 E:557 ||| IN
interaction  ||| S:557 E:569 ||| NN
was  ||| S:569 E:573 ||| VBD
observed ||| S:573 E:581 ||| VBN
.  ||| S:581 E:583 ||| .
The  ||| S:583 E:587 ||| DT
antiviral  ||| S:587 E:597 ||| JJ
effect  ||| S:597 E:604 ||| NN
of  ||| S:604 E:607 ||| IN
the  ||| S:607 E:611 ||| DT
tested  ||| S:611 E:618 ||| JJ
combinations  ||| S:618 E:631 ||| NNS
was  ||| S:631 E:635 ||| VBD
studied  ||| S:635 E:643 ||| VBN
on  ||| S:643 E:646 ||| IN
the  ||| S:646 E:650 ||| DT
model  ||| S:650 E:656 ||| NN
of  ||| S:656 E:659 ||| IN
ACG-resistant  ||| S:659 E:673 ||| JJ
viral  ||| S:673 E:679 ||| JJ
strain ||| S:679 E:685 ||| NN
.  ||| S:685 E:687 ||| .
The  ||| S:687 E:691 ||| DT
tested  ||| S:691 E:698 ||| JJ
combinations  ||| S:698 E:711 ||| NNS
could  ||| S:711 E:717 ||| MD
be  ||| S:717 E:720 ||| VB
of  ||| S:720 E:723 ||| IN
interest  ||| S:723 E:732 ||| NN
for  ||| S:732 E:736 ||| IN
practical  ||| S:736 E:746 ||| JJ
medicine ||| S:746 E:754 ||| NN
.  ||| S:754 E:756 ||| .
